Immucell (ICCC) - Potential Treatment for Cryptosporidium Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucell (ICCC) - Potential Treatment for Cryptosporidium

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ed who wrote (7)	4/18/1997 8:31:00 AM
From: Jonathan Rothschild	of 46

This seems like it will be a very quick clinical trial. Cryptogam studies face difficult accrual, but this is nothing new as the protease inhibitor cocktails are inhibiting secondarty infections in AIDS patients. Diffgam is useful for a specific form of colitis which is not uncommon. A major partnership can emerge from this drug if it is shown to be successful. What's most important is that their products are "physiological agents" derived from milk antibodies and cause few side effects, if any. FDA is more comfortable with these types of drugs. Also, they are addressing one of the most problematic issues in epidemiology, namely antibiotic resistance. Can you believe they have a 1MM cash, 5 products in development, 4 MM in revenues, an approved veterinary drug, SBO grants, a building, 20 employees and a 5 MM market cap? Another yet to be discovered gem.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next